A multidrug regimen containing brentuximab vedotin (BV, Adcetris) proved feasible for older patients with advanced classical ...

Researchers sought to determine whether SOC pola-R-CHP frontline therapy would be safe and effective in a real-world population of patients with treatment-naïve DLBCL.

Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage oncology company leveraging its proprietary RADR® artificial intelligence (AI) platform to systematically transform drug discovery paradigms, today ...

The FDA has decided not to approve glofitamab plus gemcitabine and oxaliplatin to treat certain patients with relapsed/refractory DLBCL.

Research and development collaboration program to include additional models of lymphoma and leukemia to further validate ...

Colorado Buffaloes defensive lineman Nikhil Webb Walker stood before his teammates and delivered a message that would shock ...

A new study presented at the 2025 International Conference on Malignant Lymphoma (ICML) has shown that radiation therapy can ...

Researchers recommend that details on prescription medications received in the year before diagnosis and treatment initiation be included in clinical trials as essential baseline information.

He made a conceptual leap in immunotherapy by creating a hybrid T-cell, known as CAR-T, that was genetically modified to ...

A large-scale national study of primary central nervous system lymphoma (PCNSL) in England has revealed stark differences in ...

Lantern Pharma (LTRN) announced that a heavily pretreated patient with aggressive Grade 3 non-germinal center B-cell diffuse large B-cell lymphoma ...

Finding cancer early makes it much more likely that treatment will work. There are early signs of cancer that are easy to ...